SubHero Banner
Text

February 2022

Core topics in this month’s edition include:

  • Carvykti (ciltacabtagene autoleucel) – new drug approval
  • Jardiance (empagliflozin) – expanded indication
  • Releuko (filgrastim-ayow) – new biosimilar approval

Download PDF

Text